Q3 2026 Call: CompoSecure Margin Expansion Persists, Husky Order Stabilization Not Yet Enough to Change Stance

What happened

GPGI’s Q3 2026 earnings call highlighted continued strength at CompoSecure, with segment EBITDA margin once again above 35% and record metal card volumes, reinforcing the platform’s core profit engine. Husky, however, delivered only modest sequential stabilization in orders and backlog, with management citing ongoing resin-price uncertainty and customer capex caution, but no clear inflection toward the guided 2H26 margin expansion. Consolidated adjusted EBITDA remained near the $85–90 million quarterly run-rate, but GAAP net loss persisted due to ongoing interest and transaction-related amortization, keeping free cash flow negative. Management reiterated expectations for improved Husky profitability in Q4 2026 and into 2027, citing pipeline strength and cost actions, but did not provide new quantitative targets, limiting visibility. The equity-method structure and Holdings-level debt burden continued to absorb much of the segment-level improvement, with cash interest outflows rising as flagged in prior filings.

Implication

The Q3 print does not yet meet the master report’s requirement for an upgrade—Husky’s sequential order stabilization is encouraging but marginal, and EBITDA margin improvement remains unproven. CompoSecure’s consistent 35%+ margins provide a floor for the platform, but the equity value is still dominated by the Husky recovery timeline and the $2.175B Holdings debt service burden. With free cash flow still negative and cash interest outflows rising, the stock is likely to remain range-bound between $12 and $16 until Q4 2026 results clearly demonstrate Husky’s operating leverage. The unusual insider buying seen in June at around $11.67 suggests some informed investors see value, but the structural issues (management fees, equity-method opacity) cap near-term upside. A re-rating above $18 would require Husky to deliver low-single-digit sales growth and EBITDA margin expansion of at least 200 bps in Q4 2026, which currently appears unlikely without a broader macro recovery.

Thesis delta

The investment thesis shifts slightly from “unproven recovery” to “early evidence of stabilization, but not yet inflection.” While the Q3 call confirms that Husky’s order book has stopped deteriorating, the lack of margin improvement keeps the risk/reward unattractive at current levels. We maintain a WAIT rating, but the probability of the bull case increases modestly if Q4 2026 shows the promised operating leverage.